United Therapeutics Corporation Share Price Today: Live Updates & Key Insights
United Therapeutics Corporation share price today is $524.28, up -0.52%. The stock opened at $525.9 against the previous close of $527, with an intraday high of $529.53 and low of $520.48.
United Therapeutics Corporation Share Price Chart
United Therapeutics Corporation
United Therapeutics Corporation Share Price Performance
United Therapeutics Corporation Institutional Holdings
United Therapeutics Corporation Market Status
United Therapeutics Corporation Fundamentals
Market Cap 22977.98 M
PB Ratio 3.2565
PE Ratio 18.9202
Enterprise Value 19987.72 M
Total Assets 7880.00 M
Volume 796634
United Therapeutics Corporation Company Financials
About United Therapeutics Corporation & investment objective
Company Information United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Organisation Drug Manufacturers - Specialty & Generic
Employees 1400
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
United Therapeutics Corporation FAQs
What is the share price of United Therapeutics Corporation today?
The current share price of United Therapeutics Corporation is $524.28.
Can I buy United Therapeutics Corporation shares in India?
Yes, Indian investors can buy United Therapeutics Corporation shares by opening an international trading and demat account with Motilal Oswal.
How to buy United Therapeutics Corporation shares in India?
You can easily invest in United Therapeutics Corporation shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy United Therapeutics Corporation shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of United Therapeutics Corporation.
Can I buy fractional shares of United Therapeutics Corporation?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of United Therapeutics Corporation?
United Therapeutics Corporation has a market cap of $22977.98 M.
In which sector does United Therapeutics Corporation belong?
United Therapeutics Corporation operates in the Drug Manufacturers - Specialty & Generic sector.
What documents are required to invest in United Therapeutics Corporation stocks?
To invest, you typically need:
What is the PE and PB ratio of United Therapeutics Corporation?
The PE ratio of United Therapeutics Corporation is 18.92 and the PB ratio is 3.26.